National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Glomerulosclerosis, Focal Segmental trials
The registry lists 10 Glomerulosclerosis, Focal Segmental studies with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 1Phase 2 6Phase 3 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)CompletedNCT00135811Phase 3Results posted
- Podocyte RetinoidsCompletedNCT00098020Phase 2Results posted
- Permeability Factor in Focal Segmental GlomerulosclerosisCompletedNCT00007475Phase 1/2Results posted
- Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)CompletedNCT00001959Phase 2Results posted
- Rituximab Treatment of Focal Segmental GlomerulosclerosisWithdrawnNCT00550342Phase 2
- Evaluation of Albuminuria HIV-Infected PatientsCompletedNCT00524992
- Kidney Disease BiomarkersCompletedNCT00255398
- Sirolimus for Focal Segmental GlomerulosclerosisCompletedNCT00040508Phase 2
- Once-A-Month Steroid Treatment for Patients With Focal Segmental GlomerulosclerosisCompletedNCT00004990Phase 2
- Genetic Markers for Focal Segmental GlomerulosclerosisCompletedNCT00001393